Bulk Anti-Human CD28 (CD28.2) Antibody

Human

CD28

>1mg/ml

Mouse IgG1 Kappa

Mouse

Anti-Mouse CD28 (37.51) In Vivo Antibody - Low Endotoxin (ICH1055), Anti-Mouse CD28 (E18) Antibody - Low Endotoxin (ICH1239), Anti-Rat CD28 (JJ319) In Vivo Antibody - Low Endotoxin (ICH1254), Anti-Mouse CD28 (D665) In Vivo Antibody - Low Endotoxin (ICH1271), Theralizumab Biosimilar - Research Grade (ICH5023)

Aggregation level ≤ 5%

Mature T cells, thymocytes, NK cell subsets, plasma cells, EBV-positive B cells

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P10747

Blue ice

This is a bulk-format anti-human CD28 monoclonal antibody, clone CD28.2, a mouse IgG1 kappa raised against human CD28. CD28.2 is a widely characterised clone that recognises the extracellular domain of human CD28 and is broadly used to study T-cell costimulation and activation. The antibody is validated for flow cytometry, immunohistochemistry on frozen sections, and functional assays, making it suitable for both phenotyping and mechanistic in-vitro work. Because it reacts with human CD28, it is well suited to studies using primary human T cells, PBMCs, and human cell lines, including T-cell activation and expansion protocols. Supplied as a research-use-only (RUO) reagent in bulk milligram-to-gram quantities at low endotoxin levels, it is appropriate for cell-culture and functional applications where reagent purity and lot consistency matter. The bulk, low-endotoxin format supports scaled or repeated experiments such as large PBMC expansions, assay development, and standardised functional readouts, while keeping per-milligram cost predictable for high-throughput or long-running human immunology programmes. CD28 is the principal costimulatory receptor on T cells and the prototypical "signal 2" for T-cell activation. It is a disulphide-linked homodimeric glycoprotein of the immunoglobulin superfamily, expressed constitutively on most CD4+ and a large fraction of CD8+ T cells. CD28 binds the B7 ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells. When engaged together with T-cell receptor recognition of peptide-MHC, CD28 signalling lowers the activation threshold, promotes IL-2 production, drives clonal expansion, supports survival through anti-apoptotic gene expression, and shapes effector differentiation. In the absence of CD28 costimulation, TCR engagement alone can drive anergy or tolerance. CD28 shares its ligands with the inhibitory receptor CTLA-4, which competes for B7 binding and counterbalances costimulation. Because of this central role, CD28 is a key node in immune regulation and immunotherapy research.

TP44, CD28 2, CD28-2, CD282

CD28.2

Anti-CD28 In Vivo Antibody - Low Endotoxin (CD28.2) recognizes an epitope on Human CD28

This monoclonal antibody was purified using Protein A

0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.

anti-CD28 In Vivo Antibody - Low Endotoxin (CD28.2) is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

IHC (Frozen), Flow Cytometry, Functional Assays

Each investigator should determine their own optimal working dilution for specific applications.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is clone CD28.2 suitable for in vivo and functional use?

A: Yes, CD28.2 is supplied in a low-endotoxin, in vivo-grade format suitable for T-cell costimulation studies and in vitro work.

Q: Can I order clone CD28.2 anti-CD28 in bulk?

A: Yes, it is produced in scalable milligram to gram quantities for bulk and high-throughput experiments.

Q: What is clone CD28.2 used for?

A: CD28.2 is an anti-human CD28 monoclonal antibody used to study T-cell costimulation; for research use only.